Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced the promotion of Ethan Mohan to executive vice president.
Mohan, who previously held the position of sales manager, has driven the company’s sales strategies and strategic partnerships, the company said on Tuesday.
In his new role, Mohan will oversee corporate strategy, business development, and international market expansion initiatives in support of Voyageur’s mission to deliver high-quality and sustainable barium and iodide-based healthcare products.
Brent Willis, Voyageur CEO, said Mohan’s promotion positions the company to capitalize on emerging global opportunities.
“Ethan brings a rare combination of scientific expertise and entrepreneurial acumen that we expect will directly lead to the development of commercial success for Voyageur,” Willis said.
“As we move forward with the development of Frances Creek, navigate FDA regulatory pathways, and scale our international footprint, Ethan’s strategic insight and executional drive will be critical to propelling Voyageur into its next phase of expansion.”
Mohan expressed enthusiasm about joining the company.
“Voyageur believes its steadfast commitment to the development of barium and iodine-based contrast agents will position it to lead the market with a portfolio that is not only sustainable and cost-efficient, but purpose-built to elevate standards of care worldwide,” Mohan said.
“By delivering high-quality, affordable contrast media, Voyageur aims to ease the burden on healthcare systems and enhance patient outcomes globally.”